Anavex Life Sciences Corp (AVXL)

[Investor2014]

The pharma world is slowly waking up to the therapeutic potential of S1R and S2R, realising that S1R affinity of previously approved drugs have been overlooked or ignored.

Here is a recent study of Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors that has parallels the realisation that some of the effects of Donepezil appears to stem from its affinity to S1R as an agonist.

Conclusions
The present study demonstrated that Riv potentiates NGF-induced neurite outgrowth in PC12 cells and that both Sig-1R and Sig-2R play a role in the mechanism of this effect. Therefore, it is thought that both Sig-1R and Sig-2R are involved in the pharmacological action of Riv in humans. Furthermore, agents such as Riv that target Sig-1R and Sig-2R may enhance the effect of NGF, playing an important role in the therapeutic treatment of AD in the future.